CardioFocus has announced that more than 10,000 patients worldwide have been treated with the HeartLight endoscopic ablation system.
The HeartLight system is a catheter ablation technology for controlled and consistent pulmonary vein isolation (PVI), the gold standard treatment for atrial fibrillation (AF). HeartLight is a treatment option for some patients whose AF is insufficiently controlled with medication.
In May the US Food and Drug Administration (FDA) approved the next-generation HeartLight X3 system. This offers a RAPID mode, which includes precise motor control that enables uninterrupted, high-speed, circumferential lesion creation under direct visual control of the physician resulting in consistently reduced procedure times, CardioFocus said in a press release.
“As an early adopter of the HeartLight system, I have seen first-hand the benefits this transformational technology provides AF patients,” said Henry D Huang, a cardiac electrophysiologist at Rush University Medical Center, Chicago, USA. “The speed, control, predictability and durability of HeartLight X3 are unparalleled and allow us to customise the treatment based on the unique needs of each patient.”
More than 33 million patients worldwide suffer from AF which has been associated with significant symptoms, functional impairment, stroke, cognitive decline, heart failure, and reduced longevity.
“We are committed to providing our AF patients with the latest advancements in cardiac treatments, including devices like the HeartLight X3 System,” said David N Kenigsberg, clinical cardiac electrophysiologist and medical director of the electrophysiology laboratory at Westside Regional Medical Center in Plantation, USA. “I am honoured to be among the group of electrophysiologists helping to achieve the 10,000 patient HeartLight milestone and furthering the reach of this revolutionary technology.”
“CardioFocus values our partners and the leaders in the electrophysiology community who have made this noteworthy milestone a reality. Their collaboration and unwavering commitment to exceptional patient care have expedited the adoption of this technology at a remarkable pace,” said Burke T Barrett, chief executive officer & president at CardioFocus.